Cost-effectiveness of a potential prophylactic helicobacter pylori vaccine in the united states

Journal of Infectious Diseases

Volumn 200, Issue 8, 2009, Pages 1311-1317

  Rupnow, Mareia F T ^a,d   Chang, Alicia H ^b,d,e   Shachter, Ross D ^a   Owens, Douglas K ^b,c   Parsonnet, Julie ^b  

^a Stanford University   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^d ETHICON INC   (United States)

^e NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HELICOBACTER PYLORI VACCINE;

ADOLESCENT; ARTICLE; CHILD; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; GROUPS BY AGE; HELICOBACTER INFECTION; HUMAN; INFANT; INFECTION PREVENTION; NEWBORN; PRESCHOOL CHILD; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SCHOOL CHILD; SIMULATION; STOMACH CANCER; UNITED STATES; VACCINATION;

EID: 70349427180     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/605845     Document Type: Article

References (45)

1. Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 2007; 102:1808-1825
2. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007;56:772-781
3. Talley NJ, Vakil N. Guidelines for the management of dyspepsia. Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 2005; 100:2324-2337
4. Zullo A, De Francesco V, Hassan C, Morini S, Vaira D. The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis. Gut 2007;56:1353-1357
5. Rijpkema SG. Prospects for therapeutic Helicobacter pylori vaccines. J Med Microbiol 1999;48:1-3.
6. Michetti P. Vaccine against Helicobacter pylori:, feet or fiction? Gut 1997; 41:728-730
7. Meyer JM, Silliman NP, Wang W, et al. Risk factors for Helicobacter pylori resistance in the United States: the surveillance of H pylori antimicrobial resistance partnership (SHARP) study, 1993-1999. Ann Intern Med 2002; 136:13-24.
8. Kumala W, Rani A Patterns of Helicobacter pylori isolate resistance to fluoroquinolones, amoxicillin, clarithromycin and metronidazoles. Southeast Asian J Trop Med Public Health 2006; 37:970-974
9. Wong BC, Lam SK, Wong WM, et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 2004;291:187-194
10. Rupnow MF, Shachter RD, Owens DK, Parsonnet J. A dynamic transmission model for predicting trends in Helicobacter pylori and associated diseases in the United States. Emerg Infect Dis 2000; 6:228-237
11. Rupnow MF, Shachter RD, Owens DK, Parsonnet J. Quantifying the population impact of a prophylactic Helicobacter pylori vaccine. Vaccine 2001;20:879-885
12. Stratton KR, Durch JS, Lawrence RS, eds. Vaccines for the 21st century: a tool for decisionmaking. Committee to Study Priorities for Vaccine Development. Washington, DC: National Academies Press, 2000:476.
13. Graham DY. Helicobacter pylori: its epidemiology and its role in duodenal ulcer disease. J Gastroenterol Hepatol 1991;6:105-113
14. Kuipers EJ. Helicobacter pylori and the risk and management of associated diseases: gastritis, ulcer disease, atrophic gastritis and gastric cancer. Aliment Pharmacol Ther 1997; 11(Suppl 1):71-88.
15. Valle J, Kekki M, Sipponen P, Ihamaki T, Siurala M. Long-term course and consequences of Helicobacter pylori gastritis: results of a 32-year follow-up study. Scand J Gastroenterol 1996;31:546-550
16. Hansson L.-E. Nyren O. Hsing A.W. Bergstrom R. Josefsson S. Chow W.-H. Fraumeni J.F. Jr. Adami H.-O. The risk of stomach cancer in patients with gastric or duodenal ulcer disease New England Journal of Medicine 1996 335 4 242-249 DOI 10.1056/NEJM199607253350404 16. Hansson LE, Nyren O, Hsing AW, et al. The risk of stomach cancer in patients with gastric or duodenal ulcer disease. N Engl J Med 1996;335:242-249 (Pubitemid 26249572)
17. Sipponen P. Kekki M. Haapakoski J. Gastric cancer risk in chronic atrophic gastritis: Statistical calculations of cross-sectional data International Journal of Cancer 1985 35 2 173-177 DOI 10.1002/ijc.2910350206 17. Sipponen P, Kekki M, Haapakoski J, Ihamaki T, Siurala M. Gastric cancer risk in chronic atrophic gastritis: statistical calculations of crosssectional data. Int J Cancer 1985;35:173-177 (Pubitemid 16179958)
18. Parsonnet J, Harris RA, Hack HM, Owens DK. Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials. Lancet 1996;348:150-154
19. Fendrick AM, Chernew ME, Hirth RA, Bloom BS, Bandekar RR, Scheiman JM. Clinical and economic effects of population-based Helicobacter pylori screening to prevent gastric cancer. Arch Intern Med 1999; 159: 142-148
20. Rubin RJ, Cascade EF, Peura DA, Wilcox CM, Mendelson DN. Diagnosis and eradication of Helicobacter pylori in the management of peptic ulcer disease: a decision analysis model. Am J Manag Care 1996;2:375-383
21. Ebell M.H. Warbasse L. Brenner C. Evaluation of the dyspeptic patient: A cost-utility study Journal of Family Practice 1997 44 6 545-555 21. Ebell MH, Warbasse L, Brenner C. Evaluation of the dyspeptic patient: a cost-utility study. J Fam Pract 1997;44:545-555 (Pubitemid 27255346)
22. Willems JS, Sanders CR. Cost-effectiveness and cost-benefit analyses of vaccines. J Infect Dis 1981; 144:486-493
23. Glaspy J. Bukowski R. Steinberg D. Taylor C. Tchekmedyian S. Vadhan-Raj S. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice Journal of Clinical Oncology 1997 15 3 1218-1234 23. Glaspy J, Bukowski R, Steinberg D, Taylor Q Tchekmedyian S, VadhanRaj S. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol 1997;15:1218-1234 (Pubitemid 27106310)
24. Barosi G. Marchetti M. Liberato N.L. Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy induced anaemia British Journal of Cancer 1998 78 6 781-787 24. Barosi G, Marchetti M, Liberato NL. Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia. Br J Cancer 1998;78:781-787 (Pubitemid 28418314)
25. Office of Management and Budget. Budget of the United States government: fiscal year 2000. Available at: http://www.gpoaccess.gov/usbudget/fy00/index. html. Accessed 25 July 2009.
26. Lipscomb J, Weinstein MC, Torrance GW Time preference. In: Gold MR, Siegel JE, Russel LB, Weinstein MC, eds. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996; 214-216
27. Centers for Medicare & Medicaid Services. National Health Expenditures Tables. Available at: http://www.cms.hhs.gov/ NationalHealthExpendData/downloads/tables.pdf. Accessed 13 June 2008.
28. Storskrubb T, Aro P, Ronkainen J, et al. Serum biomarkers provide an accurate method for diagnosis of atrophic gastritis in a general population: the Kalixanda study. Scand J Gastroenterol 2008;43:1448-1455
29. Yanaoka K, Oka M Mukoubayashi Q et al. Cancer high-risk subjects identified by serum pepsinogen tests: outcomes after 10-year follow-up in asymptomatic middle-aged males. Cancer Epidemiol Biomarkers Prev 2008; 17:838-845
30. Krishnan HS, Schaefer M. Evaluation of the impact of pharmacist's advice giving on the outcomes of self-medication in patients suffering from dyspepsia. Pharm World Sei 2000;22:102-108
31. Furu K. Straume B. Use of antacids in a general population. The impact of health-related variables, lifestyle and sociodemographic characteristics Journal of Clinical Epidemiology 1999 52 6 509-516 DOI 10.1016/S0895-4356(99) 00020-7, PII S0895435699000207 31. Furu K, Straume B. Use of antacids in a general population: the impact of health-related variables, lifestyle and sociodemographic characteristics. J Clin Epidemiol 1999; 52:509-516 (Pubitemid 29281668)
32. Penston JG, Pounder RE. A survey of dyspepsia in Great Britain. Aliment Pharmacol Ther 1996; 10:83-89
33. Shahabi S, Rasmi Y, Jazani NH, Hassan ZM. Protective effects of Helicobacter pylori against gastroesophageal reflux disease may be due to a neuroimmunological anti-inflammatory mechanism. Immunol Cell Biol 2008;86:175-178
34. Raghunath A, Hungin AP, Wooff D, Childs S. Prevalence of Helicobacter pylori in patients with gastro-oesophageal reflux disease: systematic review. BMJ 2003; 326:737.
35. de Martel C, Llosa AE, Farr SM, et al. Helicobacter pylori infection and the risk of development of esophageal adenocarcinoma. J Infect Dis 2005; 191:761-767
36. Wong A. Fitzgerald R.C. Epidemiologic risk factors for Barrett's esophagus and associated adenocarcinoma Clinical Gastroenterology and Hepatology 2005 3 1 1-10 DOI 10.1016/S1542-3565(04)00602-0, PII S1542356504006020 36. Wong A, Fitzgerald RC. Epidemiologic risk factors for Barrett's esophagus and associated adenocarcinoma. Clin Gastroenterol Hepatol 2005;3:1-10. (Pubitemid 40092937)
37. Herbarth O, Bauer M, Fritz GJ, et al. Helicobacter pylori colonisation and eczema. J Epidemiol Community Health 2007;61:638-640
38. Perry S, Sanchez L, Yang S, Haggerty TD, Hurst P, Parsonnet J. Helicobacter pylori and risk of gastroenteritis. J Infect Dis 2004; 190:303-310
39. Luzza F, Parrello T, Sebkova L, et al. Expression of proinflammatory and ThI but not Th2 cytokines is enhanced in gastric mucosa of Helicobacter pylori infected children. Dig Liver Dis 2001;33:14-20.
40. Sheikh A, Strachan DP. The hygiene theory: feet or fiction? Curr Opin Otolaryngol Head Neck Surg 2004; 12:232-236
41. Cremonini F, Gasbarrini A. Atopy, Helicobacter pylori and the hygiene hypothesis. Eur J Gastroenterol Hepatol 2003; 15:635-636
42. Li GQ, Chen MH, Zhu SL, et al. Therapeutic vaccination against Helicobacter pylori infection with attenuated recombinant Salmonella typhimurium urease B subunit and catalase in mice. Chin J Dig Dis 2004;5:72-75
43. Sutton P, O'Rourke J, Wilson J, Dixon MF, Lee A. Immunisation against Helicobacter felis infection protects against the development of gastric MALT lymphoma. Vaccine 2004;22:2541-2546
44. Kim JS, Chang JH, Chung SI, Yum JS. Importance of the host genetic background on immune responses to Helicobacter pylori infection and therapeutic vaccine efficacy. FEMS Immunol Med Microbiol 2001;31: 41-46
45. Chui SY, Clay TM, Lyerly HK, Morse MA. The development of therapeutic and preventive vaccines for gastric cancer and Helicobacter pylori. Cancer Epidemiol Biomarkers Prev 2005; 14:1883-1889